EPIDEMIOLOGY OF POST-COVID SYNDROME
Abstract
As per the World Health Organization's (WHO) definition, post-COVID syndrome or long COVID refers to the persistence or emergence of new symptoms three months after the initial infection with the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus 2), and lasting for a minimum of two months, while excluding alternative diagnoses. The precise mechanisms responsible for the development of long COVID19 symptoms have yet to be fully understood. The prevalence of post-COVID syndrome exhibits considerable variation, mostly influenced by factors like as study design, study population, and the specific case definition employed in the study. Based on some estimations, a minimum of 10% of those exhibiting a severe clinical manifestation of SARS-CoV-2 viral infection are likely to have post-COVID syndrome. This condition is characterized by multisystemic involvement, presenting a diverse spectrum of symptoms that impact several bodily systems, including but not limited to the respiratory, cardiovascular, musculoskeletal, neurological systems and skin. The prevailing manifestations of prolonged COVID-19 encompass fatigue, dyspnea, and cognitive impairment. Nonetheless, a spectrum of over 200 distinct symptoms have been documented, which can significantly impede the day-to-day capabilities of those afflicted with the condition. Based on data derived from both the United States and Europe, it has been shown that the incidence of long COVID syndrome has a greater frequency among the female population and individuals afflicted with chronic conditions. Considering the global prevalence of individuals affected by the SARS-CoV-2 virus, it is imperative to conduct ongoing epidemiological surveillance to gain a consistent understanding of the current situation. Additionally, it is crucial to perform research, primarily utilizing representative population samples, to enhance our understanding of risk factors and identify potential preventive measures. This knowledge would also contribute to the identification of population groups with a higher susceptibility to the onset of post-COVID syndrome, which holds significant value in comprehending the enduring consequences of the COVID-19 pandemic.
References
2. Ahmad MS, Shaik RA, Ahmad RK, Yusuf M, Khan M, Almutairi AB, et al. "LONG COVID": an insight. Eur Rev Med Pharmacol Sci. 2021 Sep; 25(17):5561-5577.
3. WHO. Post COVID-19 condition (Long COVID). https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition, pristupljeno 12. 11. 2023. godine
4. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Global Health. 2021 Sep; 6(9):e005427.
5. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr; 27(4):601-615.
6. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022 Nov; 226:1593–607.
7. Centers for Disease Control and Prevention. Long COVID. 2023. Dostupno na: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm. Pristupljeno 12.11. 2023.
8. Davis HE, McCorkell L, Vogel JM, Topol EJ. ‘Long COVID: major findings, mechanisms and recommendations’. Nature Reviews Microbiology. 2023 Mar: 133–146.
9. Centers for Disease Control and Prevention. COVID data tracker. 2020. Dostupno na: https://covid.cdc.gov/covid-data-tracker/#inspire.
10. Bull-Otterson L, Baca S, Saydah S, Boehmer K. Tegan, Adjei Stacey, Gray Simone, et al. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years United States, March 2020– November 2021. MMWR Morb Mortal Wkly Rep 2022; 71:713–7.
11. Saydah SH, Brooks JT, Jackson BR. Surveillance for post-COVID conditions is necessary: addressing the challenges with multiple approaches. J Gen Intern Med 2022 May; 37:1786–8.
12. Centers for Disease Control and Prevention. Long COVID. 2022. Dostupno na: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm.
13. Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones HE, McNairy M, et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis. 2023 May; 76(9):1636-1645.
14. Ayoubkhani D, King S, Pawelek P. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK—Office for National Statistics. 2022. Dostupno na: https://www.ons.gov.uk/peoplepopulationandcommunity/healt handsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptoms followingcoronaviruscovid19infectionintheuk/7july2022.
15. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023, pristupljeno 12. novembra 2023
16. European Centre for Disease Prevention and Control (ECDC). Prevalence of post COVID-19 condition symptoms: a systematic review and meta-analysis of cohort study data, stratified by recruitment setting 31 Oct 2022 [Available from: https://www.ecdc.europa.eu/en/publications-data/prevalence-post- covid-19-condition-symptoms-systematic-review-and-meta-analysis
17. Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. Infection. 2021 Dec; 49(6):1163–86.
18. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, de Maertens C, et al. Pathophysiology and mechanism of long COVID: a compre- hensive review. Ann Med. 2022 Dec; 54(1):1473–87.
19. Hirschtick JL, Xie Y, Slocum E, Hirschtick RE, Power LE, Elliott MR, et al. A statewide population-based approach to examining Long COVID symptom prevalence and predictors in Michigan. Prev Med. 2023 Nov:107752.
20. Global Burden of Disease Long COVID Collaborators; Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022 Oct; 328(16): 1604-1615.
21. McMullan C, Chandan JS, Haroon S, Price G, Davies EH, Nirantharakumar K, et al; TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021 Sep; 114(9):428-442.
22. Thi Khanh HN, Cornelissen L, Castanares-Zapatero D, De Pauw R, Van Cauteren D, Demarest S, et al. Association between SARS-CoV-2 variants and post COVID-19 condition: findings from a longitudinal cohort study in the Belgian adult population. BMC Infect Dis. 2023 Nov; 23(1):774.
23. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. The Lancet. 2022 Oct; 399(10343):2263–4.
24. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021 Oct; 21:626–36.
25. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022 Apr; 386:1532–46.
26. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med. 2022 May; 386: 1804–16.
27. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic omicron infections. N Engl J Med. 2022; 387: 21–34.
28. Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med. 2023 Feb; 29(2):358-365.
29. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies—United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:606–8.
30. Mahase E. Covid-19: vaccinated people are less likely to get long Covid, review finds. BMJ. 2022 Feb; 376:o407.
31. Patient Safety Learning. The effectiveness of vaccination against long Covid: a rapid evidence briefing (February 2022). Patient Safety Learning—the Hub. 2022. Dostupno na: https://www.pslhub.org/learn/coronavirus-covid19/data-and- statistics/the-effectiveness-of-vaccination-against-long-covid-a-rapid-evidence-briefing- february-2022-r6159/.
32. Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine. 2022 Aug; 53:101624.
33. Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022 Jun; 13:3528.
34. Fernández-de-Las-Peñas C, Pellicer-Valero OJ, Navarro-Pardo E, et al. Symptoms experienced at the acute phase of SARS-CoV-2 infection as risk factor of long- term post-COVID symptoms: the LONG-COVID-EXP-CM multicenter study. Int J Infect. Dis 2022 mar; 116:241–4.
35.Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E. Post-acute sequelae of SARS-CoV-2 infection among adults aged ≥18 years—Long Beach, California, April 1-December 10, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:1274–7.
36. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 Apr; 27:626–31.
37. Cristillo V, Pilotto A, Cotti Piccinelli S, Bonzi G, Canale A, Gipponi S, et al. Premorbid vulnerability and disease severity impact on long-COVID cognitive impairment. Aging Clin Exp Res. 2022 Jan; 34:257–60.
38. Behnood SA, Shafran R, Bennett SD, Zhang AXD, O'Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis of controlled and uncontrolled studies. J Infect. 2022 Feb; 84:158–70.
39. COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Published correction appears in Lancet. 2022;399(10334):1468. Lancet. 2022 Apr;399(10334):1469-1488.